US2022054726A1PendingUtilityA1
System and method for removal of immune inhibitors from biological fluids
Est. expiryNov 19, 2039(~13.3 yrs left)· nominal 20-yr term from priority
G01N 33/54313C07K 14/70578G01N 2333/70578G01N 33/54366G01N 33/6863C07K 14/525A61M 1/3679A61M 2202/0415A61M 1/36A61M 1/3496A61M 1/362
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.
Claims
exact text as granted — not AI-modified1 - 41 . (canceled)
42 . A column for extracorporeal removal of a soluble tumor necrosis factor receptor (sTNF-R) from plasma of a patient, the column comprising:
a compartment configured such that the plasma passes through the compartment; and a capture support disposed within the compartment;
wherein the capture support has a leaching rate of less than 1670 ng/min.
43 . The column of claim 42 , wherein the leaching rate is less than 50 ng/min.
44 . The column of claim 43 , wherein the leaching rate is less than 10 ng/min.
45 . The column of claim 42 , wherein:
the capture support has a volume; the leaching rate is less than 150 ng/min per ml of capture support.
46 . The column of claim 45 , wherein the leaching rate is less than 50 ng/min per ml of capture support.
47 . The column of claim 46 , wherein the leaching rate is less than 10 ng/min per ml of capture support.
48 . The column of claim 42 , wherein the capture agent comprises a portion of a tumor necrosis factor (TNF).
49 . The column of claim 48 , wherein the capture agent comprises a single chain TNF.
50 . The column of claim 49 , wherein the single chain TNF comprises at least three TNF monomers or portions thereof.
51 . The column of claim 42 , wherein the sTNF-R comprises a TNF-R1.
52 . The column of claim 42 , wherein the sTNF-R comprises a TNF-R2.
53 . The column of claim 42 , wherein the leaching rate is an average over 30 seconds of flow of the plasma through the column.
54 . The column of claim 42 , wherein the column exhibits the leaching rate during the first five minutes of flow.
55 . The column of claim 42 , wherein the leaching rate is an average over 2 hours of flow of the plasma through the column.
56 . The column of claim 42 , wherein the column exhibits the leaching rate at any time during flow of the plasma through the column.Join the waitlist — get patent alerts
Track US2022054726A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.